Iris International Seeks Reimbursement For Its Prostate Molecular Dx
This article was originally published in The Gray Sheet
Executive Summary
The firm, soon to be acquired by Danaher, is pursuing a major data collection effort to gain reimbursement for its ultrasensitive prostate cancer assay, following a 300-patient trial to support 510(k) clearance.